Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Fineline Cube Aug 25, 2026
Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Fineline Cube Aug 25, 2026
Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Fineline Cube Aug 25, 2026
Company Drug

Wuhan YZY Biopharma Initiates Phase II Study for M701 in Malignant Pleural Effusion Treatment

Fineline Cube Mar 27, 2024

Wuhan YZY Biopharma Co., Ltd (HKG: 2496), a biopharmaceutical company based in China, has announced...

Company Medical Device

Acotec Scientific Receives NMPA Approval for Innovative Cardiovascular Devices

Fineline Cube Mar 27, 2024

Acotec Scientific Holdings Ltd (HKG: 6669), a leading medical device company based in China, has...

Company

Sanofi Launches KiDS Program in China to Boost Health Literacy in Schools

Fineline Cube Mar 27, 2024

Olivier Charmeil, Executive Vice-President for General Medicines at France-based Sanofi S.A. (NASDAQ: SNY), visited China...

Company

WuXi Bio Reports 2023 Revenue Growth Amid COVID-19 Business Loss and Geopolitical Tensions

Fineline Cube Mar 27, 2024

WuXi Bio (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...

Company Drug

Innovent Biologics Initiates Phase III Neoshot Study for MSI-H/dMMR Colon Cancer Treatment

Fineline Cube Mar 27, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...

Company Drug

Alexion’s Ultomiris Secures FDA Approval for Anti-AQP4 Positive NMOSD Treatment

Fineline Cube Mar 27, 2024

AstraZeneca’s (AZ; NASDAQ: AZN) rare disease unit, Alexion, has registered its biologic Ultomiris (ravulizumab) with...

Policy / Regulatory

NMPA Mandates Electronic Permits for Anesthetic Drugs and Psychotropic Substances

Fineline Cube Mar 27, 2024

The National Medical Products Administration (NMPA) has issued a new notification aimed at enhancing the...

Company

Shanghai Fosun Pharma Reports 2023 Revenues, Highlights Innovation and R&D Progress

Fineline Cube Mar 27, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company Deals

AbbVie Acquires Landos Biopharma to Boost Autoimmune Disease Pipeline

Fineline Cube Mar 27, 2024

AbbVie (NYSE: ABBV) has announced its acquisition of Landos Biopharma (NASDAQ: LABP), a biopharmaceutical company...

Policy / Regulatory

National Drug Sampling Inspection Report Reveals High Compliance Rates in 2023

Fineline Cube Mar 27, 2024

The National Institute for Food and Drug Control (NIFDC) has released its “National Drug Sampling...

Company Drug

MSD’s Winrevair Approved by FDA as First Activin Signaling Inhibitor for Pulmonary Arterial Hypertension

Fineline Cube Mar 27, 2024

The US Food and Drug Administration (FDA) has granted Merck, Sharp & Dohme (MSD; NYSE:...

Policy / Regulatory

China’s National Adverse Drug Reaction Report for 2023 Highlights Stability in Reporting Trends

Fineline Cube Mar 27, 2024

The National Center for ADR Monitoring has released its “National Adverse Drug Reaction Monitoring Annual...

Company

Lee’s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs

Fineline Cube Mar 27, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading pharmaceutical company based in China, has released...

Company

Hansoh Pharmaceutical Group Reports 7.7% YOY Revenue Growth and Expands R&D Spending

Fineline Cube Mar 27, 2024

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced its financial results for 2023, reporting...

Company Deals

Shanghai Pharmaceuticals, SHC, and CEMCS CAS Renew Partnership to Incubate Pharmaceutical Innovations

Fineline Cube Mar 27, 2024

Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, SHA: 601607; HKG: 2607), a leading pharmaceutical company in...

Company Policy / Regulatory

Kobayashi Pharmaceutical Recalls Red Yeast Rice Pills in China Amid Health Concerns

Fineline Cube Mar 26, 2024

Japan-based Kobayashi Pharmaceutical has reportedly initiated a product recall in the Chinese market for its...

Company Policy / Regulatory

Surprise Resignation: Congressman Gallagher Steps Down as Biosecure Act Faces Uncertainty

Fineline Cube Mar 26, 2024

U.S. Congressman Mike Gallagher, the key proponent behind the recently introduced Biosecure Act aimed at...

Company Deals

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Deal Amid Biotech Pressures

Fineline Cube Mar 26, 2024

U.S.-based biotech Nuvation Bio Inc. (NYSE: NUVB) has announced a definitive agreement to acquire China-based...

Company Drug

FDA Grants Full Approval to AbbVie’s Elahere for Advanced Ovarian Cancer Treatment

Fineline Cube Mar 26, 2024

This week, the U.S. Food and Drug Administration (FDA) granted full approval to AbbVie’s (NYSE:...

Company Deals Hospital

Fosun Health and Adventist Medical Center Partner to Enhance GBA Medical Services

Fineline Cube Mar 26, 2024

China-based Fosun Health Consumption Industry Group has entered into a strategic partnership with Hong Kong’s...

Posts pagination

1 … 429 430 431 … 711

Recent updates

  • Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA
  • WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%
  • China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration
  • Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines
  • Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Legal / IP

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

Company

WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%

Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.